P276
- Product NameP276
- CAS920113-03-7
- CBNumberCB32668296
- MFC21H21Cl2NO5
- MW438.3
- MDL NumberMFCD26960898
- MOL File920113-03-7.mol
Chemical Properties
| storage temp. | Store at -20° C |
| solubility | Soluble in DMSO |
| form | Solid |
| color | Off-white to light yellow |
P276 Chemical Properties,Usage,Production
Uses
P276-00 is a cyclin-dependent kinase (CDK) inhibitor. P276-00 has shown to be highly selective for cancer cells and has shown to produce potent inhibition of Cdk4-D1 activity. P276-00 also induces apoptosis in human promyelocytic leukemia (HL-60) cells.Enzyme inhibitor
This cell cycle-inhibiting flavone and anticancer agent (FW = 438.30 g/mol; CAS 920113-03-7), also named 2-(2-chlorophenyl)-5,7-dihydroxy-8- [(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4- one, targets the Cyclin-Dependent Kinases CDK1 (IC50 = 79 nM), CDK4 (IC50 = 63 nM) and CDK9 (IC50 = 20 nM). p276-00 showed potent antiproliferative effects against various human cancer cell lines (IC50 values ranging from 300 to 800 nmol/L), but has little effect on cultured fibroblasts. A significant down-regulation of cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser(780) phosphorylation is observed. P276-00 produces potent inhibition of Cdk4-D1 activity that is competitive with ATP, and not with retinoblastoma protein. The compound also induced apoptosis in human promyelocytic leukemia (HL-60) cells, as evidenced by the induction of caspase-3 and DNA ladder studies. In 22 human cancer xenografts, P276-00 is approximately 26x more potent than cisplatin, and is also active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers. Synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells are arrested in G1in vivo
Riviciclib hydrochloride (administered i.p.; 35 kg/mg daily for 10 days, in human xenograft mode with severe combined immunodeficient mice) shows significant inhibition in the growth of human colon carcinoma HCT-116 xenograft[3].
Riviciclib hydrochloride (administered via i.p.; 50 mg/kg once daily; 30 mg/kg twice daily for 18 treatments, in human xenograft mode with severe combined immunodeficient mice) significantly inhibited growth[3].
| Animal Model: | Human xenograft mode with HCT-116 tumor model (severe combined immunodeficient mice)[3] |
| Dosage: | 35 mg/kg |
| Administration: | Administered i.p.; daily for 10 days |
| Result: | Given 35 mg/kg showed significant inhibition in the growth. |
| Animal Model: | Human xenograft model with H-460 tumor xenograft (severe combined immunodeficient mice)[3] |
| Dosage: | 50 mg/kg; 30 mg/kg |
| Administration: | Administered i.p.; 50 mg/kg once daily for 20 days; Administered i.p.; 30 mg/kg twice daily for 18 treatments |
| Result: | Given 50 mg/kg and 30 mg/kg twice daily significantly inhibited growth. |
IC 50
CDK9- Cyclin T1: 0.020 μM (IC50); cdk4-cyclin D1: 0.063 μM (IC50); CDK1-Cyclin B: 0.079 μM (IC50); cdk2-cyclin A: 0.224 μM (IC50); cdk2-cyclin E: 2.500 μM (IC50); cdk6-cyclin D3: 0.396 μM (IC50); CDK9-cyclin H: 2.900 μM (IC50)P276 Suppliers
Global(75)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| +91-22-45045900 | sales@clearsynth.com | Hyderabad,India | 6093 | 58 | |
| +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | 32430 | 58 | ||
| +86-0371-86658258 +86-13203830695 | laboratory@coreychem.com | 30202 | 58 | ||
| +86-29-81148696 +86-15129568250 | 1022@dideu.com | 29083 | 58 | ||
| +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | 6377 | 58 | ||
| +86-18051384581 | sales@chemhifuture.com | 3122 | 58 | ||
| +1-781-999-5354; | support@targetmol.com | 38999 | 58 | ||
| market@chemtour.com | 1517 | 58 | |||
| +86-18327326525 | masar@topule.com | 8432 | 58 | ||
| tp@aladdinsci.com | 54707 | 58 |